XBiotech (STU:4XB) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:4XB XBiotech Inc STU:4XB
38 GF Score
Price €1.96
GF Value €0.15
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is XBiotech Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:4XB
38GF Score
XBiotech Inc STU:4XB
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is XBiotech (STU:4XB) Overvalued in 2026?

Based on GuruFocus' analysis, XBiotech stock appears to be overvalued. The current stock price of €1.96 is trading 1206.7% above its estimated GF Value™ of €0.15. GuruFocus considers XBiotech to be Significantly Overvalued.

Key valuation signals for STU:4XB:

  • Short Ratio:
  • GF Value™: €0.15 vs. price of €1.96 (1206.7% above fair value)
  • GF Score™: 38/100 with 2 warning signs

No single metric tells the full story. See the STU:4XB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


XBiotech Business Description

Other Exchanges XBIT:USA
Address 5217 Winnebago Lane, Austin, TX, USA, 78744
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
38GF Score

Get the complete analysis for STU:4XB

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.96
Price
€0.15
GF Value